ALNY

Alnylam Pharmaceuticals Stock Analysis

AI Rating

Good
  • Quality3/10
  • Growth↑ 9/10
  • Value↓ 2/10
Alnylam Pharmaceuticals sales and earnings growth
ALNY Growth
Great
  • Revenue Y/Y↑ 78.21%
  • EPS Y/Y↑ 343.58%
  • FCF Y/Y↑ 928.78%
Alnylam Pharmaceuticals gross and profit margin trends
ALNY Profitability
Great
  • Gross margin ↑ 80.80%
  • EPS margin↑ 13.50%
  • ROIC 5Y↑ -1.80%
Alnylam Pharmaceuticals net debt vs free cash flow
ALNY Risk
Fair
  • Debt / Equity↑ 2.8
  • Debt / FCF↓ 2.0
  • Interest coverage↓ 3.1

Alnylam Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Fair risk rating.

↗ More Biotechnology stocks